サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654397

症候群マルチプレックス診断の市場規模、シェア、動向分析レポート：タイプ別、最終用途別、地域別、セグメント予測、2025年～2030年

Syndromic Multiplex Diagnostics Market Size, Share & Trends Analysis Report By Type (Respiratory, Gastrointestinal, Central Nervous System), By End Use (Hospitals, Diagnostic Laboratories, Others), By Region And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
症候群マルチプレックス診断の市場規模、シェア、動向分析レポート：タイプ別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年01月29日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

症候群マルチプレックス診断市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の症候群マルチプレックス診断市場規模は2030年までに36億6,000万米ドルに達すると予測され、2025～2030年のCAGRは3.91％で拡大する見込みです。

同市場の成長は、診断技術の技術的進歩、様々な疾患の有病率の上昇、迅速で正確な診断ソリューションに対する需要の高まり、世界の高齢化などの要因によるものです。

従来の診断検査は複数のステップを必要とし、結果が出るまでに時間がかかることが多かったが、症候群マルチプレックス診断は1つのサンプルで複数の病原体を同時に検査することで包括的なソリューションを記載しています。この機能により診断にかかる時間が大幅に短縮されるため、迅速な診断が好まれる様々な医療現場での需要が高まっています。さらに、呼吸器疾患や消化器疾患など、効果的な診断ソリューションを必要とする様々な疾患の有病率が高いことも、市場成長の一因となっています。例えば、米国疾病予防管理センター（CDC）によると、2023年には米国で240万例以上の梅毒、淋病、クラミジアが診断され、文書化されました。この合計には、20万9,000例以上の梅毒、60万例以上の淋病、160万例以上のクラミジアが含まれます。このような感染症の有病率の高さは、予測期間中の市場成長を促進すると予想されます。

さらに、市場参入企業による研究開発努力の増加は、新しい診断ソリューションの開発につながり、エンドユーザー向けの複数の診断製品の利用可能性を高めています。例えば、シンガポールは2021年1月、MiRXESが開発したマルチプレックス診断キット「Fortitude SARS-CoV-2 & Flu A/B Test」を発売しました。この検査はSARS-CoV-2とインフルエンザA/Bを検出・鑑別し、より正確な診断を記載しています。このキットはシンガポールの保健科学庁（HSA）から暫定認可を受けた。より良い結果を提供するこのような効果的なソリューションの開発は、これらのソリューションの採用を増加させ、市場成長を促進すると予想されます。

ポイントオブケア検査（POCT）への需要の高まりも市場成長に寄与しています。特に遠隔地や医療サービスが行き届いていない地域での迅速診断の需要が高まる中、マルチプレックス診断システムは、1回の検査で複数の病原体や疾患を同時に検出できるため、大きなメリットをもたらします。さらに、アジア、ラテンアメリカ、中東・アフリカなどの地域では、医療インフラの改善に注力しており、より迅速で正確な結果を提供できる統合診断システムの導入が促進されています。

症候群マルチプレックス診断市場レポートハイライト

  • タイプ別では、呼吸器疾患が2024年に最大の市場シェアを占めます。これは、さまざまな呼吸器感染症の有病率の上昇と、効果的な診断技術の利用可能性の上昇に起因します。
  • 最終用途別では、診断ラボセグメントが2024年に最大の市場シェアを占めました。これは、これらの施設では患者の出入りが多く、患者へのアクセスが良いことに起因しています。
  • 地域別では、北米が市場を独占し、2024年には41.85%のシェアを占めました。北米の症候群マルチプレックス診断産業は、主要市場参入企業の存在、規制状況の進展、医療インフラの整備、各種感染症の流行拡大などを背景に大きく成長しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 症候群マルチプレックス診断市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助的な市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 症候群マルチプレックス診断市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析

第4章 症候群マルチプレックス診断市場：タイプ別、推定・動向分析

  • セグメントダッシュボード
  • 症候群マルチプレックス診断市場：タイプ変動分析
  • 症候群マルチプレックス診断市場の規模と動向分析、タイプ別、2018～2030年
  • 呼吸器
  • 胃腸
  • 中枢神経系
  • その他のタイプの症候群（cUTIとSTD）

第5章 症候群マルチプレックス診断市場：最終用途別、推定・動向分析

  • セグメントダッシュボード
  • 症候群マルチプレックス診断市場：最終用途変動分析
  • 症候群マルチプレックス診断市場の規模と動向分析、最終用途別、2018～2030年
  • 病院
  • 診断ラボ
  • その他

第6章 症候群マルチプレックス診断市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2023年と2030年
  • 地域別市場ダッシュボード
  • 世界地域市場のスナップショット
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店とチャネルパートナー一覧
    • 主要企業の市場シェア分析、2023年
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd
    • Qiagen
    • bioMerieux
    • DiaSorin SpA（Luminex Corporation）
    • Hologic, Inc.
    • Becton, Dickinson and Company（BD）
    • Applied BioCode
    • QIAGEN
    • Curetis GmbH
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America syndromic multiplex diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 8 Canada syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 10 Mexico syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe syndromic multiplex diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Germany syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 15 Germany syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 16 UK syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 17 UK syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 18 France syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 19 France syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Italy syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 21 Italy syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Spain syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 23 Spain syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Denmark syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 25 Denmark syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Sweden syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 27 Sweden syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 29 Norway syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific syndromic multiplex diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 33 China syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 34 China syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Japan syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 36 Japan syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 37 India syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 38 India syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 40 South Korea syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Australia syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 42 Australia syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Thailand syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 44 Thailand syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 46 Latin America syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Brazil syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 48 Brazil syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Argentina syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 50 Argentina syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 51 MEA syndromic multiplex diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 52 MEA syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 53 MEA syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 54 South Africa syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Africa syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 58 UAE syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 59 UAE syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 60 Kuwait syndromic multiplex diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 61 Kuwait syndromic multiplex diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Syndromic multiplex diagnostics market: market outlook
  • Fig. 14 Syndromic multiplex diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Syndromic multiplex diagnostics market driver impact
  • Fig. 20 Syndromic multiplex diagnostics market restraint impact
  • Fig. 21 Syndromic multiplex diagnostics market strategic initiatives analysis
  • Fig. 22 Syndromic multiplex diagnostics market: Type movement analysis
  • Fig. 23 Syndromic multiplex diagnostics market: Type outlook and key takeaways
  • Fig. 24 Respiratory market estimates and forecasts, 2018 - 2030
  • Fig. 25 Gastrointestinal market estimates and forecasts, 2018 - 2030
  • Fig. 26 Central nervous system market estimates and forecasts, 2018 - 2030
  • Fig. 27 Other types of syndromes (cUTI and STDs) market estimates and forecasts, 2018 - 2030
  • Fig. 28 Syndromic multiplex diagnostics market: End Use movement analysis
  • Fig. 29 Syndromic multiplex diagnostics market: End Use outlook and key takeaways
  • Fig. 30 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 31 Diagnostic laboratories market estimates and forecasts, 2018 - 2030
  • Fig. 32 Others market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global syndromic multiplex diagnostics market: Regional movement analysis
  • Fig. 34 Global syndromic multiplex diagnostics market: Regional outlook and key takeaways
  • Fig. 35 Global syndromic multiplex diagnostics market share and leading players
  • Fig. 36 North America market share and leading players
  • Fig. 37 Europe market share and leading players
  • Fig. 38 Asia Pacific market share and leading players
  • Fig. 39 Latin America market share and leading players
  • Fig. 40 Middle East & Africa market share and leading players
  • Fig. 41 North America, by country
  • Fig. 42 North America
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 46 Canada country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 48 Mexico country dynamics
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 50 Europe
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK country dynamics
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 56 France country dynamics
  • Fig. 57 France market estimates and forecasts, 2018 - 2030
  • Fig. 58 Italy country dynamics
  • Fig. 59 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 60 Spain country dynamics
  • Fig. 61 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 62 Denmark country dynamics
  • Fig. 63 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 64 Sweden country dynamics
  • Fig. 65 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 66 Norway country dynamics
  • Fig. 67 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 68 Asia Pacific
  • Fig. 69 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 70 China country dynamics
  • Fig. 71 China market estimates and forecasts, 2018 - 2030
  • Fig. 72 Japan country dynamics
  • Fig. 73 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 74 India country dynamics
  • Fig. 75 India market estimates and forecasts, 2018 - 2030
  • Fig. 76 Thailand country dynamics
  • Fig. 77 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 78 South Korea country dynamics
  • Fig. 79 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 80 Australia country dynamics
  • Fig. 81 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 82 Latin America
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 84 Brazil country dynamics
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 86 Argentina country dynamics
  • Fig. 87 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 88 Middle East and Africa
  • Fig. 89 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 90 South Africa country dynamics
  • Fig. 91 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 92 Saudi Arabia country dynamics
  • Fig. 93 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 94 UAE country dynamics
  • Fig. 95 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 96 Kuwait country dynamics
  • Fig. 97 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 98 Market share of key market players - Syndromic multiplex diagnostics market, 2023
  • Fig. 99 Company Categorization
目次
Product Code: GVR-4-68040-507-5

Syndromic Multiplex Diagnostics Market Growth & Trends:

The global syndromic multiplex diagnostics market size is anticipated to reach USD 3.66 billion by 2030, and it is expected to expand at a CAGR of 3.91% from 2025 - 2030, according to a new report by Grand View Research, Inc. The market's growth is attributed to factors such as technological advancements in diagnostics technologies, rising prevalence various diseases, growing demand for rapid and accurate diagnostics solutions, and global aging population.

Traditional diagnostic tests often require multiple steps and take longer to deliver results, whereas syndromic multiplex diagnostics offer a comprehensive solution by testing for multiple pathogens simultaneously in a single sample. This capability significantly reduces the time for diagnosis, increasing their demand in various healthcare settings where rapid diagnostics are preferred. Moreover, the high prevalence of various conditions, such as respiratory diseases, gastrointestinal conditions, and others, requiring effective diagnostics solutions further contributes to the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2023, more than 2.4 million instances of syphilis, gonorrhea, and chlamydia were diagnosed and documented in the U.S. This total includes over 209,000 syphilis cases, over 600,000 gonorrhea cases, and more than 1.6 million chlamydia cases. This high prevalence of infectious diseases is expected to fuel the market growth over the forecast period.

Moreover, the increasing R&D efforts by market players are leading to the development of new diagnostics solutions, increasing the availability of multiple diagnostics products for the end users. For instance, in January 2021, Singapore launched the Fortitude SARS-CoV-2 & Flu A/B Test, a multiplex diagnostic kit developed by MiRXES. This test detects and differentiates SARS-CoV-2 and influenza A/B, providing more accurate diagnoses. The kit received Provisional Authorisation from Singapore's Health Sciences Authority (HSA). The development of such effective solutions offering better results is expected to increase the adoption of these solutions and drive market growth.

The growing demand for Point-of-Care Testing (POCT) also contributes to market growth. With the rise in the demand for rapid diagnosis, especially in remote or underserved regions, multiplex diagnostic systems offer significant advantages by allowing for the simultaneous detection of multiple pathogens or diseases with a single test. Additionally, focuses on improving the healthcare infrastructure in regions such as Asia, Latin America and MEA are encouraging the implementation of integrated diagnostic systems that can provide faster and more accurate results.

Syndromic Multiplex Diagnostics Market Report Highlights:

  • Based on type, the bipolar respiratory segment held the largest market share in 2024. This is attributed to the rising prevalence of various respiratory infections and rising availability of effective diagnostics technologies.
  • Based on end use, the diagnostics laboratories segment held the largest market share in 2024. This is attributed to the high patient footfall in these facilities and their better accessibility to patients.
  • Based on region, North America dominated the market and accounted for a 41.85% share in 2024. The syndromic multiplex diagnostics industry in North America is experiencing significant growth driven by the presence of key market players, evolving regulatory landscape, developed healthcare infrastructure, and increasing prevalence of various infectious diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Syndromic Multiplex Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of infectious diseases
      • 3.2.1.2. Advancements in diagnostics technologies
      • 3.2.1.3. Growing demand for effective diagnostics solutions
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of syndromic diagnostics solutions
  • 3.3. Syndromic Multiplex Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Syndromic Multiplex Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Syndromic Multiplex Diagnostics Market: Type Movement Analysis
  • 4.3. Syndromic Multiplex Diagnostics Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Respiratory
    • 4.4.1. Respiratory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Gastrointestinal
    • 4.5.1. Gastrointestinal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Central Nervous System
    • 4.6.1. Central Nervous System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Other Types of Syndromes (cUTI and STDs)
    • 4.7.1. Other Types of Syndromes (cUTI and STDs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Syndromic Multiplex Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Syndromic Multiplex Diagnostics Market: End Use Movement Analysis
  • 5.3. Syndromic Multiplex Diagnostics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Diagnostic Laboratories
    • 5.5.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Syndromic Multiplex Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/Reimbursement
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/Reimbursement
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/Reimbursement
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/Reimbursement
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/Reimbursement
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/Reimbursement
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/Reimbursement
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/Reimbursement
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/Reimbursement
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/Reimbursement
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/Reimbursement
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/Reimbursement
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/Reimbursement
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/Reimbursement
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/Reimbursement
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/Reimbursement
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/Reimbursement
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/Reimbursement
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/Reimbursement
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/Reimbursement
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/Reimbursement
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/Reimbursement
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Abbott Laboratories
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Services benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Thermo Fisher Scientific, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Services benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. F. Hoffmann-La Roche Ltd
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Services benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Qiagen
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Services benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. bioMerieux
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Services benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. DiaSorin S.p.A (Luminex Corporation)
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Services benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Hologic, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Services benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Becton, Dickinson and Company (BD)
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Services benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Applied BioCode
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Services benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. QIAGEN
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Services benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Curetis GmbH
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Services benchmarking
      • 7.3.14.4. Strategic initiatives